ND0612, an investigational formulation of carbidopa/levodopa delivered continuously via a subcutaneous pump, was generally well-tolerated for more than four years of treatment in a Phase 2 clinical trial of Parkinson’s patients, new data show. Findings reveal that the vast majority of adverse events (side effects) reported in…
Continuous delivery of carbidopa/levodopa (CD/LD) with ND0612 under the skin led to quick improvement of clinical status and better quality of life for patients with advanced Parkinson’s disease, according to patient-reported outcomes from a Phase 2 clinical trial. Now, a global Phase 3 study named BouNDless (NCT04006210) is…
A new Phase 3 clinical trial, called the “BouNDless study,” will soon compare continuous administration of ND0612 to oral immediate-release carbidopa/levodopa (CD/LD) in people with Parkinson’s disease who are experiencing motor fluctuations, Mitsubishi Tanabe Pharma America (MTPA) announced. Both of the above-mentioned treatments work by increasing the level of…
Get regular updates to your inbox.
